

Amir Reza Aref

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4872690/publications.pdf>

Version: 2024-02-01

56
papers

6,832
citations

136950

32
h-index

144013

57
g-index

57
all docs

57
docs citations

57
times ranked

11672
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
2	Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. <i>Molecular Cancer</i> , 2019, 18, 75.	19.2	853
3	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	9.4	503
4	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.9	451
5	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	9.4	392
6	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2014, 26, 909-922.	16.8	376
7	Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healing. <i>Advanced Drug Delivery Reviews</i> , 2018, 123, 33-64.	13.7	339
8	Personalized Cancer Medicine: An Organoid Approach. <i>Trends in Biotechnology</i> , 2018, 36, 358-371.	9.3	185
9	3D microfluidic <i>ex vivo</i> culture of organotypic tumor spheroids to model immune checkpoint blockade. <i>Lab on A Chip</i> , 2018, 18, 3129-3143.	6.0	185
10	Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 381-389.	1.3	150
11	Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. <i>Oncogene</i> , 2020, 39, 953-974.	5.9	146
12	Long non-coding RNAs in the doxorubicin resistance of cancer cells. <i>Cancer Letters</i> , 2021, 508, 104-114.	7.2	118
13	New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111824.	5.6	106
14	Microfluidic systems for stem cell-based neural tissue engineering. <i>Lab on A Chip</i> , 2016, 16, 2551-2571.	6.0	100
15	Hyaluronic acid-based nanoplatfoms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression. <i>Carbohydrate Polymers</i> , 2021, 272, 118491.	10.2	100
16	Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects. <i>Phytotherapy Research</i> , 2022, 36, 189-213.	5.8	94
17	Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16971-16980.	7.1	92
18	Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. <i>Pharmacological Research</i> , 2021, 171, 105759.	7.1	90

#	ARTICLE	IF	CITATIONS
19	The long and short non-coding RNAs modulating EZH2 signaling in cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, 18.	17.0	89
20	Microfluidic Brain-on-a-Chip: Perspectives for Mimicking Neural System Disorders. <i>Molecular Neurobiology</i> , 2019, 56, 8489-8512.	4.0	84
21	Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. <i>Pharmacological Research</i> , 2021, 167, 105575.	7.1	84
22	Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. <i>Cancer Immunology Research</i> , 2016, 4, 520-530.	3.4	79
23	Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy. <i>Life Sciences</i> , 2021, 277, 119430.	4.3	68
24	Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems. <i>Life Sciences</i> , 2021, 275, 119368.	4.3	63
25	Optical assays based on colloidal inorganic nanoparticles. <i>Analyst, The</i> , 2018, 143, 3249-3283.	3.5	58
26	The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators. <i>Life Sciences</i> , 2021, 268, 119005.	4.3	55
27	Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112963.	5.6	47
28	Crosstalk between ferroptosis and the epithelial-mesenchymal transition: Implications for inflammation and cancer therapy. <i>Cytokine and Growth Factor Reviews</i> , 2022, 64, 33-45.	7.2	45
29	Non-coding RNA-based regulation of inflammation. <i>Seminars in Immunology</i> , 2022, 59, 101606.	5.6	40
30	The role of SOX family transcription factors in gastric cancer. <i>International Journal of Biological Macromolecules</i> , 2021, 180, 608-624.	7.5	39
31	Photoluminescent functionalized carbon dots for CRISPR delivery: synthesis, optimization and cellular investigation. <i>Nanotechnology</i> , 2019, 30, 135101.	2.6	38
32	Carbon nanotubes in microfluidic lab-on-a-chip technology: current trends and future perspectives. <i>Microfluidics and Nanofluidics</i> , 2017, 21, 1.	2.2	36
33	Transforming growth factor-beta (TGF- β) in prostate cancer: A dual function mediator?. <i>International Journal of Biological Macromolecules</i> , 2022, 206, 435-452.	7.5	34
34	Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. <i>International Journal of Biological Macromolecules</i> , 2021, 191, 727-737.	7.5	33
35	Gene regulation by antisense transcription: A focus on neurological and cancer diseases. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112265.	5.6	33
36	Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies. <i>Life Sciences</i> , 2022, 288, 119948.	4.3	26

#	ARTICLE	IF	CITATIONS
37	Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2021, 236, 3918-3928.	4.1	25
38	The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets. <i>European Journal of Pharmacology</i> , 2021, 908, 174344.	3.5	25
39	Exosomes as Promising Nanostructures in Diabetes Mellitus: From Insulin Sensitivity to Ameliorating Diabetic Complications. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1229-1253.	6.7	25
40	Validation of a Vasculogenesis Microfluidic Model for Radiobiological Studies of the Human Microvasculature. <i>Advanced Materials Technologies</i> , 2019, 4, 1800726.	5.8	23
41	Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. <i>Cancer Cell International</i> , 2020, 20, 288.	4.1	22
42	EMT signaling: potential contribution of CRISPR/Cas gene editing. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 2701-2722.	5.4	22
43	Crosstalk between lncRNAs in the apoptotic pathway and therapeutic targets in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2022, 65, 61-74.	7.2	21
44	Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKK and SRC inhibits epithelial-mesenchymal transition in cancer. <i>Briefings in Bioinformatics</i> , 2019, 20, 717-731.	6.5	20
45	Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2020, 20, 1049.	2.6	19
46	Breast cancer risk factors in Iran: a systematic review & meta-analysis. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.7	19
47	Cervical cancer progression is regulated by SOX transcription factors: Revealing signaling networks and therapeutic strategies. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112335.	5.6	19
48	MicroRNAs regulating SOX2 in cancer progression and therapy response. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e13.	3.9	17
49	Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. <i>Life Sciences</i> , 2022, 298, 120463.	4.3	17
50	Targeting AMPK signaling in ischemic/reperfusion injury: From molecular mechanism to pharmacological interventions. <i>Cellular Signalling</i> , 2022, 94, 110323.	3.6	15
51	Polyethylenimine-Functionalized Carbon Dots for Delivery of CRISPR/Cas9 Complexes. <i>ACS Applied Bio Materials</i> , 2021, 4, 7979-7992.	4.6	14
52	Crosstalk between non-coding RNAs expression profile, drug resistance and immune response in breast cancer. <i>Pharmacological Research</i> , 2022, 176, 106041.	7.1	14
53	Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. <i>Journal of Cellular Physiology</i> , 2022, 237, 2309-2344.	4.1	11
54	Aggregate Forms of Recombinant Human Erythropoietin With Different Charge Profile Substantially Impact Biological Activities. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 277-283.	3.3	4

#	ARTICLE	IF	CITATIONS
55	Generation of Induced Pluripotent Cancer Cells from Glioblastoma Multiform Cell Lines. Cellular Reprogramming, 2019, 21, 238-248.	0.9	3
56	The Effects of Sesquiterpene Lactones on the Differentiation of Human or Animal Cells Cultured In-Vitro: A Critical Systematic Review. Frontiers in Pharmacology, 2022, 13, 862446.	3.5	3